A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients

Inclusion Criteria:Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved labelPatients who are willing to provide written informed consent prior to study enrollmentExclusion Criteria:Patients under 12 years oldPatients with contraindication according to locally approved label of Jakavi®Patients who receive or are going to receive any investigational medicine during the observation period.